Induction of MASH in three-dimensional bioprinted human liver tissue
PLOS ONE · 30.12.2024 · 19 (12) · e0312615
DOI: 10.1371/journal.pone.0312615 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 30.12.2024. Verfasst von Vaidehi Joshi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Organovo, Inc., San Diego, California, United States of America. Hauptthemen laut MEDLINE: Bioprinting, Liver, Printing, Three-Dimensional, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAAA NIH HHS, NIDDK NIH HHS, Foundation for the National Institutes of Health.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (MASH), is a major risk factor for cirrhosis and hepatocellular carcinoma (HCC) and a leading cause of liver transplantation. MASH is caused by an accumulation of toxic fat molecules in the hepatocyte which leads to inflammation and fibrosis. Inadequate human “MASH in a dish” models have limited our advances in understanding MASH pathogenesis and in drug discovery. This study uses complex multicellular 3D bioprinting, combining hepatocytes with nonparenchymal cells in physiologically relevant cell ratios using biocompatible hydrogels to generate bioinks Bioprinted human liver tissues consisting of the four major cell types, (hepatocytes, liver endothelial cells, Kupffer cells, and hepatic stellate cells) are generated from cells purified from normal human livers, using this complex bioprinting platform. These liver tissues are incubated in a cocktail consisting of fatty acids, lipopolysaccharide (LPS), and fructose to produce a MASH phenotype in comparison to liver tissues incubated in control media. Furthermore, these bioprinted liver tissues are of sufficient size to undergo histological processing and immunohistchemistry comparable to classic clinical pathological analysis. The MASH liver tissues develop hepatocyte steatosis, inflammation, and fibrosis, in response to the MASH induction media. Additionally, the transcriptome of the MASH tissues differed significantly from the healthy tissues and more closely resembled the transcriptome of biopsies of MASH livers from patients Thus, this study has developed a MASH bioprinted liver tissue suitable for studies on pathophysiology and drug discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Organovo, Inc., San Diego, California, United States of America.
- University of California, San Diego, La Jolla, California, United States of America.
- Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, United States of America.
ORCID-Profile: David A Brenner
Förderung
- NIAAA NIH HHS
- NIDDK NIH HHS
- Foundation for the National Institutes of Health
Zitieren
APA
Joshi, V., Carter, D., Chen, A. E., Murphy, K., Higgins, J. W., Gurel, M., Chilin Fuentes, D., Rosenthal, S. B., Fisch, K. M., Kisseleva, T., & Brenner, D. A. (2024). Induction of MASH in three-dimensional bioprinted human liver tissue. PLOS ONE, 19(12), e0312615. https://doi.org/10.1371/journal.pone.0312615
Vancouver
Joshi V, Carter D, Chen AE, Murphy K, Higgins JW, Gurel M, et al. Induction of MASH in three-dimensional bioprinted human liver tissue. PLOS ONE. 2024;19(12):e0312615. doi:10.1371/journal.pone.0312615
BibTeX
@article{Joshi2024,
author = {Joshi, Vaidehi and Carter, Dwayne and Chen, Alice E and Murphy, Keith and Higgins, J William and Gurel, Mediha and Chilin Fuentes, Daisy and Rosenthal, Sara Brin and Fisch, Kathleen M and Kisseleva, Tatiana and Brenner, David A},
title = {Induction of MASH in three-dimensional bioprinted human liver tissue},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {12},
pages = {e0312615},
doi = {10.1371/journal.pone.0312615}
}
EUVIMED